Morepen Laboratories Management
Management criteria checks 3/4
Morepen Laboratories' CEO is Sushil Suri, appointed in Oct 2000, has a tenure of 24.25 years. directly owns 1.22% of the company’s shares, worth ₹529.48M. The average tenure of the management team and the board of directors is 8.1 years and 5 years respectively.
Key information
Sushil Suri
Chief executive officer
₹39.1m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 24.3yrs |
| CEO ownership | 1.2% |
| Management average tenure | 8.1yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
There's Reason For Concern Over Morepen Laboratories Limited's (NSE:MOREPENLAB) Massive 30% Price Jump
Aug 20
Impressive Earnings May Not Tell The Whole Story For Morepen Laboratories (NSE:MOREPENLAB)
Aug 09Improved Earnings Required Before Morepen Laboratories Limited (NSE:MOREPENLAB) Stock's 29% Jump Looks Justified
Jul 05Does Morepen Laboratories (NSE:MOREPENLAB) Have A Healthy Balance Sheet?
Jun 13Morepen Laboratories Limited's (NSE:MOREPENLAB) Popularity With Investors Is Under Threat From Overpricing
Apr 23Morepen Laboratories (NSE:MOREPENLAB) Seems To Use Debt Quite Sensibly
Nov 23Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)
Sep 22Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?
Aug 10Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)
Sep 21Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?
Apr 05Do Morepen Laboratories's (NSE:MOREPENLAB) Earnings Warrant Your Attention?
Sep 14Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?
May 21Does Morepen Laboratories (NSE:MOREPENLAB) Deserve A Spot On Your Watchlist?
Mar 12Our View On Morepen Laboratories' (NSE:MOREPENLAB) CEO Pay
Feb 22Is Morepen Laboratories Limited's (NSE:MOREPENLAB) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Feb 07Morepen Laboratories (NSE:MOREPENLAB) Shareholders Have Enjoyed A 91% Share Price Gain
Jan 21Morepen Laboratories (NSE:MOREPENLAB) Has A Pretty Healthy Balance Sheet
Jan 03
Is There More To The Story Than Morepen Laboratories's (NSE:MOREPENLAB) Earnings Growth?
Dec 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹1b |
| Jun 30 2024 | n/a | n/a | ₹1b |
| Mar 31 2024 | ₹39m | n/a | ₹962m |
| Dec 31 2023 | n/a | n/a | ₹761m |
| Sep 30 2023 | n/a | n/a | ₹531m |
| Jun 30 2023 | n/a | n/a | ₹477m |
| Mar 31 2023 | ₹48m | ₹44m | ₹387m |
| Dec 31 2022 | n/a | n/a | ₹428m |
| Sep 30 2022 | n/a | n/a | ₹553m |
| Jun 30 2022 | n/a | n/a | ₹768m |
| Mar 31 2022 | ₹91m | ₹87m | ₹1b |
| Dec 31 2021 | n/a | n/a | ₹1b |
| Sep 30 2021 | n/a | n/a | ₹1b |
| Jun 30 2021 | n/a | n/a | ₹1b |
| Mar 31 2021 | ₹54m | ₹51m | ₹971m |
| Dec 31 2020 | n/a | n/a | ₹814m |
| Sep 30 2020 | n/a | n/a | ₹684m |
| Jun 30 2020 | n/a | n/a | ₹453m |
| Mar 31 2020 | ₹17m | ₹16m | ₹336m |
| Dec 31 2019 | n/a | n/a | ₹331m |
| Sep 30 2019 | n/a | n/a | ₹312m |
| Jun 30 2019 | n/a | n/a | ₹340m |
| Mar 31 2019 | ₹12m | ₹11m | ₹288m |
| Dec 31 2018 | n/a | n/a | ₹252m |
| Sep 30 2018 | n/a | n/a | ₹267m |
| Jun 30 2018 | n/a | n/a | ₹308m |
| Mar 31 2018 | ₹6m | ₹4m | ₹296m |
Compensation vs Market: Sushil's total compensation ($USD456.05K) is above average for companies of similar size in the Indian market ($USD256.47K).
Compensation vs Earnings: Sushil's compensation has been consistent with company performance over the past year.
CEO
Sushil Suri (60 yo)
24.3yrs
Tenure
₹39,112,000
Compensation
Mr. Sushil Suri, B.Sc., FCA has been Managing Director of Morepen Laboratories Limited since October 2000. He has been Chairman of Morepen Laboratories Limited since October 2000 and has been its Director...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & MD | 24.3yrs | ₹39.11m | 1.22% ₹ 529.5m | |
| Whole-Time Director | 10yrs | ₹21.80m | 1.01% ₹ 435.8m | |
| Chief Financial Officer | 10.4yrs | ₹9.80m | no data | |
| General Manager of Process Engineering & Technology Transfer | no data | no data | no data | |
| Manager of Administration | no data | no data | 0.58% ₹ 252.2m | |
| Company Secretary & Compliance Officer | 6.2yrs | ₹1.84m | no data | |
| Functional Head of Talent Acquisition & HRBP | less than a year | no data | no data | |
| Chief Operating Officer of API | less than a year | no data | no data | |
| Head of Medipath Division | no data | no data | 0.42% ₹ 180.3m | |
| Head of International Business Development | no data | no data | no data | |
| Chief Executive Officer of Consumer Division | no data | no data | 0.56% ₹ 241.1m | |
| Chief of R&D | no data | no data | no data |
8.1yrs
Average Tenure
47.5yo
Average Age
Experienced Management: MOREPENLAB's management team is seasoned and experienced (8.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & MD | 32.9yrs | ₹39.11m | 1.22% ₹ 529.5m | |
| Whole-Time Director | 5.4yrs | ₹21.80m | 1.01% ₹ 435.8m | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 5.4yrs | ₹520.00k | no data | |
| Independent Director | 4.6yrs | ₹300.00k | no data | |
| Independent Director | less than a year | no data | no data |
5.0yrs
Average Tenure
56yo
Average Age
Experienced Board: MOREPENLAB's board of directors are considered experienced (5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 13:58 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Morepen Laboratories Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vijay Madunala | FirstCall Research |